埃菲林-A4配体（EFNA4）预示肝细胞癌预后不良并促进肿瘤增殖。
Ephrin-A4 Ligand (EFNA4) Predicts Poor Prognosis of Hepatocellular Carcinoma and Promotes Tumor Proliferation.
作者信息
Ye Peng, Chen Zide, Lou Haibo, Mai Yanjun, Zhu Xiaolin, Fu Xihua
机构信息
Department of Infectious Diseases and Hepatology Unit, Panyu Central Hospital, Guangzhou, Guangdong, China.
Department of Interventional Radiology, Cancer Center, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong, China.
出版信息
J Clin Exp Hepatol. 2023 Sep-Oct;13(5):767-773. doi: 10.1016/j.jceh.2023.04.004. Epub 2023 Apr 15.
BACKGROUND/AIMS: Primary hepatocellular carcinoma (HCC) is one of the most lethal tumor diseases in the world. Receptor tyrosine kinases (RTKs) are thought to play a vital role in HCC and Ephrin-A4 ligand (EFNA4) is a membrane-bound molecule that can activate RTKs through erythropoietin-producing hepatocellular (Eph) receptors. However, the specific role of EFNA4 remains unknown. The aim of our study was to explore the prognostic value of EFNA4 expression in HCC.
METHODS
Bioinformatics analyses were conducted to probe the expression levels and prognostic value of EFNA4 in HCC. The quantitative real-time polymerase chain reaction, immunohistochemical and western blot were used to confirm the expression of EFNA4 in paired clinical specimens of HCC. Colony formation assay was used to confirm the proliferation of tumor cell.
RESULTS
The expression of EFNA4 is generally elevated in various cancers. Especially, EFNA4 was upregulated in tumor tissue and associated with clinical stage in HCC patients. HCC patients with lower levels of EFNA4 possessed better survival and progression-free survival times. Colony formation assay indicated that the overexpression of EFNA4 promoted tumor cell proliferation.
CONCLUSION
These results demonstrated that EFNA4 played as an oncogenic gene and a prognostic biomarker for HCC patients.
背景/目的：原发性肝细胞癌（HCC）是世界上最致命的肿瘤疾病之一。受体酪氨酸激酶（RTK）被认为在HCC中起重要作用，而Ephrin-A4配体（EFNA4）是一种膜结合分子，可通过促红细胞生成素产生肝细胞（Eph）受体激活RTK。然而，EFNA4的具体作用仍不清楚。本研究的目的是探讨EFNA4表达在HCC中的预后价值。
方法
进行生物信息学分析以探究EFNA4在HCC中的表达水平和预后价值。采用定量实时聚合酶链反应、免疫组织化学和蛋白质印迹法来证实EFNA4在HCC配对临床标本中的表达。采用集落形成试验来证实肿瘤细胞的增殖。
结果
EFNA4的表达在各种癌症中普遍升高。特别是，EFNA4在肿瘤组织中上调，且与HCC患者的临床分期相关。EFNA4水平较低的HCC患者具有更好的生存时间和无进展生存时间。集落形成试验表明，EFNA4的过表达促进肿瘤细胞增殖。
结论
这些结果表明，EFNA4是HCC患者的致癌基因和预后生物标志物。
Zotero 插件